ArticleScientific reports2026
Long-term kinetics of anti-RBD IgG antibodies 16 months after COVID-19 vaccination in Morocco: a longitudinal cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic profiling reveals immune signatures associated with potential COVID-19 susceptibility and a predictive framework in a Chinese cohort.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the long-term durability of vaccine-induced immunity is crucial for shaping public health strategy. This study aimed to evaluate the 16-month kinetics of anti-receptor-binding domain (RBD) IgG antibodies following COVID-19 vaccination in Morocco. In this longitudinal cohort study, 2,546 blood samples were collected from 1,273 participants across the Casablanca-Settat region at six and sixteen months after the last vaccine dose. Participants had received homologous or heterologous regimens with the BNT162b2, ChAdOx1‑S, or BBIBP‑CorV vaccines. Anti‑RBD IgG levels were quantified using a chemiluminescent microparticle immunoassay. Multivariable linear mixed‑effects modeling was used to evaluate associations with age, sex, vaccine platform, number of doses, prior infection, and comorbidity status. Antibody levels declined significantly between six and sixteen months among participants who received only two doses (β = -0.072, 95% CI - 0.088 to - 0.056; p < 0.001). Receipt of a third dose was independently associated with higher antibody levels (β = 0.180, 95% CI 0.070-0.290; p = 0.001), with no significant interaction between dose number and time (p = 0.717). Prior SARS‑CoV‑2 infection was associated with higher antibody levels in unadjusted analyses but was not independently associated with antibody magnitude after multivariable adjustment. Increasing age was associated with higher antibody levels (β = 0.008 per year; p < 0.001), and no significant interaction between age and time was observed (p = 0.338), indicating comparable antibody decay across age groups. A trend toward higher antibody levels in females compared with males was observed but did not reach conventional statistical significance (p = 0.052). Anti‑RBD IgG antibodies decline over time following primary vaccination but remain detectable at 16 months. Booster vaccination is independently associated with higher antibody levels. Antibody decay kinetics appear broadly comparable across subgroups based on age, sex, and dose number. These findings support continued booster vaccination strategies to sustain humoral immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.